Additional file 1 of SHMT2 regulates esophageal cancer cell progression and immune Escape by mediating m6A modification of c-myc

Supplementary Material

A Facile Route To Modify Ferrous Phosphate and Its Use as an Iron-Containing Resource for LiFePO₄ via a Polyol Process

This study introduces an economical and environmentally friendly way of synthesizing LiFePO₄/C to be used as cathode material in lithium ion batteries via two processes: (1) the synthesis of LiFePO₄/C cathode material using a low cost divalent precursor ferrous phosphate, Fe₃ (PO₄)₂·8H₂O, as iron source in a polyol process and (2) the modification of the morphology of this precursor by varying the reaction time in a coprecipitation process. The study examines the effects of different structures and morphologies of the precursor on the structure and electrochemical performance of the as-synthesized LiFePO₄/C. The LiFePO₄/C shows an excellent rate capability and cycle performance, with initial discharge capacities of 153, 128, and 106 mA h g^–1 at 1 C, 5 C, and 10 C. The capacity retention is respectively 98.7%, 98.2%, and 98.7%, after 10 cycles at the corresponding rates. The capacity retention remains at 97% even after 300 cycles at the rate of 10 C. The outstanding electrochemical performance can be attributed to the improved rate of Li⁺ diffusion and the excellent crystallinity of synthesized LiFePO₄/C powders through the modified precursor. Therefore, this is an economical and environmentally friendly way of synthesizing LiFePO₄/C to be used as cathode material in lithium ion batteries

Additional file 1: of Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

Table S1. Demographic and pathological data on brain samples. Figure S1. Characterization of AD brain extracts used for LTP experiments. (a) Half milliliter aliquots of mock immunodepleted (AD) and AW7 immunodepleted (ID-AD) extracts were analyzed by IP/WB. AW7 was used for IP and a combination of 2G3 and 21F12 was used for WB. To enable comparison 2 and 5 ng of Aβ1–42 peptide was also electrophoresed on the gel. IP/WB analysis allows the capture of Aβ structures under native conditions and their detection following denaturing SDS-PAGE. (b) The same samples were also analyzed by an MSD-based Aβx-42 immunoassay. Since GuHCl effectively disaggregates high molecular weight Aβ species, samples were analyzed with and without incubation in denaturant. Analysis of samples in the absence of GuHCl allows the measurement of native Aβ monomer, whereas, analysis of samples treated with GuHCl allows detection of disassembled aggregates. The AD extracts contained much larger amounts of aggregates than monomer, and both monomer and aggregates were effectively removed by AW7 immunodepletion. The experiments shown are typical of at least 3 separate experiments. Figure S2. Bath application of anti-Aβ antibodies had no significant effect on hippocampal LTP. Each data in this graph was average of at least 6 recordings. (DOCX 466 kb

New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials

<div><p>Background</p><p>Sevelamer hydrochloride is used widely, but its impact upon cardiovascular calcification, cardiovascular mortality, all-cause mortality and hospitalization is not known.</p><p>Outcomes</p><p>Primary outcome was cardiovascular calcification (coronary artery calcification scores (CACS) and aortic calcification scores (ACS)). Secondary outcomes were serum characteristics, hospitalization, cardiovascular mortality and all-cause mortality. Risk ratio (RR), mean differences and standard mean difference with 95% confidence intervals (CIs) were pooled using random- or fixed-effects models.</p><p>Results</p><p>We identified 31 studies (on 23 randomized controlled trials with 4395 participants). An analysis pooling showed a significant decrease in serum levels of phosphate with calcium-based phosphate binders (CBPBs) by 0.17 mg/dL [mean difference (MD), 95% CI, 0.03, 0.31] than sevelamer. A significant difference in the change of CACS by –102.66 [MD: 95% CI, –159.51, –45.80] and ACS by –1008.73 [MD, 95% CI, –1664.75, –352.72] between sevelamer and CBPBs was observed. Prevalence of hypercalcemia (serum levels of calcium >10.2–10.5 mg/dL and >11.0 mg/dL) was significantly smaller for sevelamer (RR = 0.44, 95% CI, 0.33, 0.58; RR = 0.24, 95% CI, 0.14, 0.40). No significant difference was found in hospitalization, all-cause mortality or cardiovascular mortality.</p><p>Conclusions</p><p>This meta-analysis suggests that sevelamer benefits dialysis patients in terms of CACS, ACS and hypercalcemia.</p></div

Forest plot of the values of hepercalcemia (above 11.0 mg-dL).

<p>Forest plot of the values of hepercalcemia (above 11.0 mg-dL).</p

Forest plot of sevelamer vs. calcium phosphate binders on CACS change.

<p>Forest plot of sevelamer vs. calcium phosphate binders on CACS change.</p

Forest plot of the values of phosphorus.

<p>Forest plot of the values of phosphorus.</p

Forest plot of the values of hepercalcemia (above 10.2 mg-dL).

<p>Forest plot of the values of hepercalcemia (above 10.2 mg-dL).</p

Details of the use of statins.

<p>^aNot reported</p><p>^bStatins were given to calcium group at start, to sevelamer group at week 8 only if their LDL-C levels were not less than 70 mg/dL</p><p>^c8% patients were given statins in sevelamer group, while 11% in cacium group</p><p>^d26% patients were given statins in sevelamer group, while 33% in cacium group</p><p>^eDefinitive conclusions about the role of LDL-C lowering in the progression of CAC was unavailable</p><p>^fStatin use was not associated with less progression of coronary artery or aortic calcification in sevelamer or calcium carbonate patients</p><p>Details of the use of statins.</p

Summary of the studies analyzed.

<p>^a All studies having been analyzed are included</p><p>^<b>b</b> The same data were extracted for only once</p><p>Summary of the studies analyzed.</p